Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer

Completed

• Conditions: Bladder Cancer

• Registration Number: NCT03327883
• Lead Sponsor: National Cancer Institute (NCI)

Brief Summary

Background:

Bladder cancer is a common cancer in the U.S. Survival rates for metastatic bladder cancer have not gotten better for 15 years. Diagnosing and assessing the disease is important for treating it. The best way to tell what stage a cancer is in is computed tomography. This is also called CT. But it does not always give the best images of the bladder. Adding a test called positron emission tomography (PET) can help. Magnetic resonance imaging (MRI) is even better than CT for detecting bladder cancer. But it is not widely used.

Some people with bladder cancer have already had MRI/PET and CT. Researchers want to study their records. They want to compare the different ways of assessing the disease.

Objective:

To evaluate the use of MRI/PET for diagnosing and treating metastatic bladder cancer.

Eligibility:

People 18 years and older who were in studies between 2013 and 2016

Design:

Researchers will study existing records. There will be no active participants.

The records will have no data that could identify the participants. Data will be stored on secure computers.

No study participants will be contacted without approval from a review board.

Detailed Description

This protocol is a chart review of the diagnostic imaging and management of patients with metastatic bladder cancer who have undergone PET MRI. The study will involve only review of patient records and will not use specimens or participant contact. The participants whose records will be reviewed in this protocol were enrolled on a number of different protocols between 2013 and 2016.

Study Timeline

• Study Start: 2017-10-26
• Study First Submitted: 2017-10-31
• Study First Submitted QC: 2017-10-31
• Study First Posted: 2017-11-01
• Primary Completion: 2018-02-15
• Study Completion: 2018-10-16
• Status Verified: 2021-07
• Last Update Submitted: 2021-07-08
• Last Update Posted: 2021-07-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease burden	1 year	Comparison of measure of disease burden by PET/MRI versus traditional CT imaging

Trial Locations

Locations (1)

National Cancer Institute (NCI); 🇺🇸 Bethesda, Maryland, United States